

Concept Life Sciences adds Lumito's tissue analysis solution to its customer offering following positive results from the SCIZYS platform evaluation

Lumito AB (publ) ("Lumito" or the "Company") announces that Concept Life Sciences, a leading contract research organisation (CRO) serving the global life sciences and pharma industry, has added Lumito's advanced tissue analysis technology to its customer offering, following a joint development collaboration leading to positive results from its evaluation of the SCIZYS platform.

"This is an important step forward in our collaboration and also fully in line with Lumito's established strategy; collaborating with CROs who offer tissue analysis tests based on our SCIZYS technology to their clients, enabling us to generate revenues. The fact that Concept Life Sciences, an established player, not only confirms our technological strengths but also sees a clear market value is very gratifying and affirming. Their decision to integrate our technology into their offering shows the potential of our solution", says Sanna Wallenborg, CEO of Lumito.

Lumito announced on March 27, 2025, through a press release that the Company had entered into a collaboration with Concept Life Sciences, to improve tissue analysis in drug development. The joint project focused on evaluating and optimising Lumito's technology for use in Concept Life Sciences' research services.

Since the start of the collaboration, Concept Life Sciences has conducted a comprehensive and independent evaluation of Lumito's technology, with results showing that Lumito's solution exhibits a 10x higher sensitivity compared to established technologies on the market. In addition, as announced through a press release on August 13, 2025, Lumito's samples have proven to work fully in an autostainer, which ensures high and consistent quality in laboratory analyses. Following the technical evaluation, Concept Life Sciences conducted customer dialogues to gauge market interest. The response from customers has clearly demonstrated a need for a more sensitive and faster solution.

Concept Life Sciences has now entered the commercial phase where Lumito's solution is offered to its customers. As a consequence of the excellent sensitivity and dynamic range of the SCIZYS-platform, Lumito's solution can be offered at a premium price compared with conventional IHC solutions. The commercial agreement is based on the "scanning-as-a-service" model where Lumito provides a fully encompassing solution with reagents, in-house scanning and image transfer. Tissue preparation, staining and image analysis are done by Concept Life Science in its best-in-class facility in Edinburgh, Scotland.

"After testing Lumito's technology both technically and in dialogue with our customers, we see a clear market potential. The combination of high sensitivity and compatibility with our existing systems makes the solution very attractive, both from a scientific and commercial perspective. Together, we aim to make a significant difference in drug development particularly areas such as spatial biology where accurate and measurable detection of protein can be difficult," says Chris Mills, Senior Scientist at Concept Life Sciences.

For further information, please contact:

Sanna Wallenborg, CEO Lumito

E-mail: sw@lumito.se

Ph: +4670-870 01 68

About Lumito

Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

About Concept Life Sciences

Concept Life Sciences is an innovative Contract Research Organization (CRO) dedicated to accelerating drug discovery and development through cutting-edge scientific expertise and state-of-the-art technologies. With a multidisciplinary team specializing in biology, chemistry, ADME/DMPK, and bioanalytics, they provide tailored solutions to pharmaceutical and biotech companies, helping them navigate the complexities of drug discovery from concept to clinic. www.conceptlifesciences.com

Attachments

[Concept Life Sciences adds Lumito's tissue analysis solution to its customer offering following positive results from the SCIZYS platform evaluation](#)